DCPH Stock Doubles on Late-Stage Drug Data

Just last month Deutsche Bank called the stock's eventual pop

Digital Content Manager
Aug 13, 2019 at 9:52 AM
facebook twitter linkedin

The shares of biotech name Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) have more than doubled this morning after the durgmaker announced that its lead treatment, ripretinib, met its main goal during a late-stage study in patients with stomach cancer. The stock has shot up 100% at $39.95, trading right back near its June 2018 record highs, and set for its best day ever.

Just yesterday, DCPH took a massive slide, bottoming out at seven-month lows, and was struggling right below the year-to-date breakeven. point. This plummet comes just days after the stock tried to rally off a second-quarter earnings win earlier this month, only to be met with resistance at its 200-day moving average. Today, however, the equity is set to close atop this trendline, with only one other close north of here notched since last October. 

Analysts have had high hopes for Deciphera even before today's surge, made evident by its consensus 12-month target price of $45.50, which still holds a slight premium to the stock's current perch. What's more, all but one analyst has doled out a "strong buy" rating to the equity, with the holdout calling it a "strong sell." In fact, last month Deutsche Bank called the stock's pop, initiating coverage with a $42 price target and a "buy" rating. 

While short interest has been declining, down 14.3% in the last two reporting periods, the 3.09 million shares sold short still represents a healthy 20.5% of the stock's available float. Considering that it would still take over two weeks to buy back all these bearish bets at DCPH's average pace of trading, short covering tailwinds could still occur.


Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 



Special Offers from Schaeffer's Trading Partners